

29th European Diabetic Nephropathy Study Group Meeting

May 20-21, 2016

Palazzo Blu

Entrance by Via Pietro Toselli, 27 – Pisa (Italy)





European
Diabetic
Nephropathy
Study Group
EDNSG.ORG

Friday, May 20th 2016

08.00 -09.00 Registration

09.00-09.15 Opening Ceremony – Peter Rossing, President of EDNSG

09.15-10.00

Invited Lecture 1

Chairperson: *George Jerums, Australia*

Renal lesions in patients with type 2 diabetes: a puzzle waiting to be solved - Loreto Gesualdo, Bari - Italy

10.00-11.00

Session 1 - Experimental Diabetic Nephropathy: in vitro studies

Chairpersons: *Alessia Fornoni, USA; Gabriella Gruden, Italy*

- OP-1 **PACSIN2 is increased in podocytes in diabetic nephropathy and regulates nephrin turnover at the plasma membrane** – Vincent Dumont et al, Finland
- OP-2 **Modulation of the Insulin Signaling in Human Podocytes by Sphingolipids** – Alla Mitrofanova et al, USA
- OP-3 **Role of podocyte receptor podo-GPCR2 in diabetic nephropathy** – Sonia Zambrano Sevilla et al, Sweden
- OP-4 **Cellular defense mechanisms that protect cells from Methylglyoxal-induced protein damage are up-regulated in diabetic nephropathy** – Johanna Zemva et al, Germany

11.00-11.30

Coffee and exhibition

11.30-13.00

Session 2 - Biomarkers of Diabetic Nephropathy

Chairpersons: *Robert Nelson, USA; Paola Fioretto, Italy*

- OP-5 **The CKD273 Urinary Proteomic Classifier for Early Diagnosis of Nephropathy in Type 2 Diabetes: Not Simply an Indicator of Generalised Vascular Disease** – Gemma Currie et al, United Kingdom
- OP-6 **Beta 2-Microglobulin and Kidney Injury Molecule 1 Together Improve Prediction of EGFR Decline in Type 2 Diabetes** - Helen Looker et al, United Kingdom
- OP-7 **Local TNF Alters Cellular Cholesterol Homeostasis Leading to Podocyte Apoptosis in Diabetic Kidney Disease** – Christopher Emanuel Pedigo et al, USA
- OP-8 **Elevated Circulating Monocyte Fraction Correlates with Glomerular Structure in Type 2 Diabetes** – Kevin Wheelock et al, USA
- OP-9 **Intestinal inflammation precedes diabetic nephropathy in type 1 diabetes** – Mariann Lassenius et al, Finland
- OP-10 **Capillary rarefaction is associated with (micro)albuminuria – The Maastricht Study** – Remy J. H. Martens et al, The Netherlands

13.00-14.00

Lunch

14.00-15.00

Poster Sessions and Exhibition

Parallel Poster Session 1 – Clinical Aspects

Chairperson: *Hiddo Lambers Heerspink, The Netherlands*

- PP-1 **Urinary adiponectin is associated with the slope of renal function decline in macroalbuminuric patients with type 1 diabetes mellitus** – Nicolae Mircea Panduru et al, Finland
- PP-2 **Metabolic effects of high-calorie meals on type 1 diabetic individuals with and without nephropathy (The FinnDiane Study)** – Stefan Mutter et al, Australia
- PP-3 **Demonstration of chronic kidney disease incidence estimation from prevalence and mortality data** – Meda E. Pavkov et al, USA
- PP-4 **Serum concentrations of tumor necrosis receptor 1 or 2 predict concordant risks of end-stage renal disease in type 1 and type 2 diabetes** – Jan Skupien et al, Poland
- PP-5 **Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria** – Bernt Johan von Scholten et al, Denmark

Parallel Poster Session 2 – Experimental aspects

Chairperson: *Federica Barutta, Italy*

- PP-6 **Is urinary proteomics useful to predict retinopathy in type 2 diabetic patients in the DIRECT 2 study** – Mie Klessen Eickhoff et al, Denmark
- PP-7 **Role of podocyte protein Pod-RA1 in the pathogenesis of diabetic nephropathy** – Katja Möller-Hackbarth et al, Sweden
- PP-8 **Plasma micro-RNA sequencing in patients with type 2 diabetes: results from a pilot study** – Maguelonne Roux et al, France
- PP-9 **Urine Protein Fragment Excretion in Patients with T2DM and Chronic Kidney Disease** – George Jerums et al, Australia
- PP-10 **Cell-free mitochondrial DNA in circulation in patients with diabetes and diabetic kidney disease** - Afshan Malik et al, United Kingdom
- PP-11 **Enalapril transiently reduces albuminuria and induces juxtaglomerular hypertrophy in the STZ mouse model of diabetic nephropathy** – Carola Schellack Wenander et al, Denmark

15.00-15.45

Chairperson: *Per-Henrik Groop, Finland*

Ruth Osterby Lecture “The Quest for the Holy Grail” - Carol Forsblom, Helsinki - Finland

[15.45-16.15](#)

Coffee and Exhibition

[16.15-17.45](#)

Session 3 – Clinical aspects of diabetic nephropathy: part 1

Chairpersons: *Luiza Caramori, USA; Giuseppe Penno, Italy*

- OP-11 **Diabetic kidney disease phenotypes in the Preventing Early Renal Loss in type 1 diabetes (PERL) trial** – Alessandro Doria et al, USA
- OP-12 **Mesangial matrix expansion in diabetic nephropathy (DN) is due to accumulation of worn-out GBM material** – Wilhelm Kriz et al, Germany
- OP-13 **Diabetic foot infection as a cause of significant decline in renal function among South Indian patients with Type2 diabetes mellitus** – Vijay Viswanathan et al, India
- OP-14 **Heritability of renal function decline measured by the rate of eGFR loss in T1D** – Erkkä Valo et al, Finland
- OP-15 **Identifying novel phenotype profiles of patients with T1D using machine learning approaches** – Iiro Toppila et al, Finland
- OP-16 **Linkage analysis of small pedigrees reveals multiple novel regions for diabetic nephropathy** – Jani Haukka et al, Finland

[17.45-18.30](#)

Annual General Meeting of the EDNSG

[20.00](#)

Working Dinner

Saturday, May 21st 2016

09.00-10.45

SGLT-2 Symposium

Chairpersons: *Peter Rossing, Denmark; Stefano Del Prato, Italy*

09.00-09.30

Lecture 1 – Physiology of the SGLT2 system - Volker Vallon, La Jolla – CA -USA

09.30-10.00

Lecture 2 – The EMPA-REG Outcome Study: cardiovascular and renal results – Per-Henrik Groop, Helsinki - Finland

10.00-10.30

Lecture 3 – Physiological insights into cardiorenal protection with SGLT2 inhibition - David Cherney, Toronto - Canada

10.30-10.45 - **Discussion**

10.45-11.00

Coffee and exhibition

11.00-12.00

Session 4 – Novel therapeutic opportunities

Chairpersons: *Giuseppe Pugliese, Italy; Sami Hadjadj, France*

OP-17 **Early renin-angiotensin-system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes** – Bauke Schievink et al, The Netherlands

OP-18 **Long-term effect of losartan on early kidney disease in American Indians with type 2 diabetes** – Robert G. Nelson et al, USA

OP-19 **Pleiotropic effects of GLP-1 treatment on renal risk factors in type 2 diabetes** – Emilie Hein Petersen et al, Denmark

OP-20 **Effect of bariatric surgery on vascular and renal biomarkers in morbidly obese, normotensive, non-diabetic patients** – Rosa Maria Bruno et al, Italy

12.00-13.00

Session 5 - Diabetic Nephropathy: experimental aspects

Chairpersons: *Luigi Gnudi, United Kingdom; Jaakko Patrakka, Sweden*

OP-21 **Protease-activated receptor 1 (PAR-1) potentiates diabetic nephropathy by inducing mesangial expansion** – Maaïke Waasdorp et al, The Netherlands

OP-22 **De-nitrosylation of laminin 521 in diabetic nodular glomerulosclerosis** – Alda Tufro et al, USA

OP-23 **Coro2b is a novel actin regulating protein of podocyte foot processes that may play a role in the pathogenesis of diabetic nephropathy** - Jaakko Patrakka et al, Sweden

OP-24 **Soluble Nogo-B Ameliorates Albuminuria in Diabetic Nephropathy: Role of full-length Nogo-B** – Marie Flaquer et al, United Kingdom

13.00-14.00

Lunch

14.00-14.45

Invited Lecture 3

Chairperson: *Sally Marshall, United Kingdom*

Spotlights on mortality risk factors in patients with type 2 diabetes – Vincenzo Trischitta, Rome - Italy

14.45-16.15

Session 6 - Clinical aspects of diabetic nephropathy: part 2

Chairpersons: *Lise Tarnow, Denmark; Carol Forsblom, Finland*

OP-25 **Regression of Albuminuria is associated with reduced Cardiovascular Risk in patients with Type 1 Diabetes** – Fanny Jansson et al, Finland

OP-26 **Renal function loss over 21 years of follow-up with intensified, multifactorial intervention in type 2 diabetes with microalbuminuria** – Jens Oellgaard et al, Denmark

OP-27 **Metabolic subtypes, nephropathy and cardiovascular mortality in patients with type 1 diabetes** - Raija Lithovius et al, Finland

OP-28 **Long Term Stabilization of Renal Function in Clinical Islet Transplant Recipients** – Ying Ling et al, Canada

OP-29 **Identification of a novel variant associated with kidney function: An exome-array analyses of 18,222 Europeans** - Tarunveer Singh Ahluwalia et al, Denmark

OP-30 **Non-invasive approach reveals genes that may predict the progression of DKD** – Christopher Emanuel Pedigo et al, USA

16.15-16.45

Best Communications Prizes

Closing Remarks and coffee to go